About Amylin
Amylin is a Healthcare company based in San Diego (United States) founded in 1987, and was acquired by Bristol-Myers Squibb in June 2012. Peptide hormone analogues to treat metabolic diseases. The company was acqui-hired. Its focus areas include Life Sciences, Metabolic Diseases and Drugs. Its legal entity is Amylin Pharmaceuticals LLC. Its competitors include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Amylin Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended-release). On February 4, 2014, the U.S. FDAapproved Myalept (metreleptin), an analog of human leptin, as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystroph. In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for 5.3 billion. In December 2013, Amylin was acquired by AstraZeneca
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website amylin.com
- Social LinkedIn Facebook
- Acquired by Bristol-Myers Squibb (Jun 2012)
- Legal Name Amylin Pharmaceuticals Llc
- Latest Funding Round$100M (USD), Post-IPO
Feb 2000
- Investors
- Acquired byBristol-Myers Squibb
(Jun 2012)
Funding Insights of Amylin
- Total Rounds 1
- Last Round Post-IPO — $100M
- First Round $100M
(Feb 2000)
All 1 funding rounds of Amylin with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2000 | $100M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Amylin
Amylin has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States |
Investor details for Amylin
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Amylin
1 people are tracked at Amylin (1 in leadership).
| Name | Role | Group |
|---|---|---|
Daniel M. Bradbury | CEO | Leadership |
Complete people profiles for Amylin
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Amylin
3 dated milestones of Amylin across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Amylin is founded.
- Funding First funding round of $100.0M.
- Exit Acquired by Bristol-Myers Squibb.
Competitors of Amylin
Amylin has 3 listed competitors in our database, 3 of them funded. They include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. |
Detailed competitors of Amylin
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Amylin
Websites that share an audience with Amylin (amylin.com).
Websites whose visitors overlap most with Amylin. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| auspexpharma.com | 100% | View details | |||
| onglyza.com | 97% | View details | |||
| amgen.com | 93% | 495.4K | #116,434 | View details | |
| cadilapharma.com | 92% | 18.5K | #1,452,788 | View details | |
eyeforpharma.com | eyeforpharma.com | 92% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 20 similar websites and full traffic analytics for Amylin
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Amylin (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Amylin
Complete news archive for Amylin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amylin
Amylin was founded in 1987 and raised its 1st funding round 13 years after it was founded.
Amylin is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Amylin Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended-release). On February 4, 2014, the U.S. FDAapproved Myalept (metreleptin), an analog of human leptin, as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystroph. In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for 5.3 billion. In December 2013, Amylin was acquired by AstraZeneca.
Amylin's top competitors include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals.
Amylin has 1 investor. Key investors include Bristol-Myers Squibb.
Amylin operates through Amylin Pharmaceuticals Llc.
Yes. Amylin was acquired by Bristol-Myers Squibb in June 2012.